Molecular diagnosis of congenital toxoplasmosis or disseminated toxoplasmosis is mainly 28 based on PCR. The repeated DNA element rep529 has become the main DNA target used in 29 most, whether laboratory-developed or commercial, PCR methods. In this multicenter study, 30 we evaluated the Toxoplasma ELITe MGB® (Elitech®) commercial kit, by comparison with 31 three reference quantitative PCR assays (RA) used in routine in three proficient laboratories 32 of the French National Reference Center for Toxoplasmosis network, using Toxoplasma 33 calibrated suspensions diluted to obtain a range of concentrations from 0.1 to 10,000 34 parasites/mL. These suspensions were extracted either with the DNA extraction kit 35 (EXTRAblood®, Elitech®) recommended by the manufacturer or the QIAamp DNA-minikit 36 (Qiagen). The Toxoplasma ELITe MGB® assay was also evaluated on a panel of 128 clinical 37 samples, including 56 amniotic fluid, 55 placenta, and various other samples, of which 95 38 originated from patients with proven toxoplasmosis. The ELITe MGB assay amplified less 39 frequently low-concentration replicates (<10 parasites/mL) of calibrated suspensions, than 40 the RA of 2/3 laboratories. Additionally, the combination EXTRAblood® / Toxoplasma ELITe 41 MGB® yielded poorer sensitivity than the combination QIAmp DNA-minikit/ ELITe MGB® for 42 low parasite concentrations (p<0.001 for 1 parasite/mL). On clinical samples, the sensitivity 43 and the specificity of the commercial assay were 89% and 100%, respectively. The sensitivity 44 ranged from 79% to 100% with placenta and amniotic fluid samples, respectively. Overall, 45 this study shows that the Toxoplasma ELITe MGB® assay is suitable for the diagnosis of 46 toxoplasmosis from non-cell-rich or non-hemoglobin-rich samples, and that the 47 EXTRAblood® kit is not optimal. accession number AF146527), as the sensitivity provided using this DNA target has proved 61 higher than that of the formerly used B1 gene in most studies (2-5). About three quarters of 62 these reference laboratories still use 'in-house' or laboratory-developed rtPCR techniques 63 which have been evaluated in clinical studies; but there is an increasing trend to use 64 commercial assays, which, in spite of being more expensive, are easier to use and allow a 65 better quality management than the former. The manufacturers of these kits announce a 66 sensitivity threshold, but the performance of these assays may be altered by the tested 67 sample type or the DNA extraction method used. Indeed, Toxoplasma may be searched not 
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DNA was previously extracted from the suspension in each center using their routine 93 method for molecular diagnosis (here, QIAamp DNA mini-kit®, Qiagen, Les Ulis, France). The 94 three labs compared the sensitivity of detection of serial dilutions (from 10,000 95 tachyzoites/mL to 0.1/mL) after amplification using their own in-house PCR method (so-96 5 called reference assay (RAs , Table 1 ) and the Toxoplasma ELITe MGB® kit, following the 97 manufacturer's instructions. All dilution points were amplified in triplicate or quadruplicate. 98 Another batch of calibrated suspension was extracted in parallel, using either the manual using the QIAamp DNA mini-kit®), 2 µL of Elitech IC was added in 10 µL of template DNA, and 163 10 µL of this solution were used for amplification, as suggested by the manufacturer. 164 The assay has been validated only on Applied Biosystems devices. In this study, ELITe MGB® 
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Comparative testing using Toxoplasma calibrated suspensions 190 The first step of the study was to determine the PCR performance scores using serial 191 dilutions of calibrated Toxoplasma DNA suspension. PCR performance scores were 192 9 calculated as described elsewhere (7, 15), using the T. gondii (Tg) DNA serial dilution assay, 193 and are reported in Table 2 . In all three centers, the scores obtained using the in-house 194 method and the Elitech® assay were close, but the RA method had a higher score than the 195 commercial assay in two out of three centers (p<0.01, Table 2 ). Taken together, the lowest 196 parasite concentrations, i.e. "1" and "0.1" Toxoplasma/mL, were inconstantly amplified. For Comparative testing using clinical samples 208 When using clinical samples, the concordance between the in-house method and the Elite 209 MGB® assay was 92% (118/128). All negative DNAs were tested negative (33/33); but false 210 negative results were obtained using the Elite MGB® kit as compared with the RAs for 10 out 211 of 95 positive samples, yielding a specificity of 100% and a relative sensitivity of 89.5% for 212 the kit. This sensitivity was 100% for AF (38/38) and other fluid samples (AH, CSF), but only 213 79% (34/43) for placenta and 80% (4/5) for buffy coat samples (Table 3 ). In 9/10 cases, the 214 false negative results were obtained for placenta samples with high Ct values (>37). To rule 215 out PCR inhibition, samples were diluted to 1/10 th and re-tested. Additionally, as the nature 216 10 of the Elitech® IC was not known and could be suspected to interfere with small amounts of 217 parasite DNA, these false negative samples were also tested without IC. Amplification was 218 restored from plain DNA in the absence of IC (2 cases, with Ct of 39.7 and 40.7) and after 219 dilution to 1/10 th and absence of IC in one case (Ct = 36.7). No amplification was observed 220 after dilution to 1/10 th when IC was not removed. 221 Overall, the sensitivity for fluid samples was higher than for cellular samples (100% versus 222 80%, p<0.01)( Table 3) . 223 Finally, the qualitative results obtained using the QCMD® 2014 quality control samples were 224 concordant for the RA1 and Elite MGB® assays (7/7 positive samples and 3/3 negative 225 samples; Table 3 ). Mean Cts obtained with both techniques were not statistically different 226 (p=0.8, data not shown). (Figure 2A) . Surprisingly, at the "1 Tg/mL" concentration, the 235 mean Ct was significantly lower when the IC was withdrawn from the extraction and 236 amplification steps than that obtained after extraction with EXTRAblood® including IC (33.57 237 ±0.93 versus 38.75 ±1.18, p<0.001) (Figure 2A) . Similarly, the addition of the IC to the mix of 238 amplification also led to an increase of the mean Ct at the "1 Tg/mL" concentration (33.57 239 ±0.93 versus 37.97 ±0.007, p<0.001). In another experiment, both extraction methods ELITe MGB® assay showed similar performance as the three laboratory-developed reference 257 methods down to 10 T.g/mL, but the lowest concentrations were inconstantly detected 258 (Table 2) , despite a higher DNA input into the amplification reaction (10 µL) than in the 259 reference methods (Table 1) . 260 When using clinical samples, the Toxoplasma ELITe MGB® assay showed a 100% sensitivity assays, the Ct obtained for IC was always < 30, thus it could be reasonably considered that 287 the test was valid; yet false negative results have been found. 288 As the DNA extraction method is also known to influence the performance of PCR 289 amplification (18), we decided to compare the Ct results of calibrated parasite suspensions, 290 extracted using either the extraction kit (EXTRAblood®) as recommended by the 291 manufacturer, or the QIAamp DNA blood mini-kit®, as routinely done in the three labs. 292 Subsequent amplification with the RA1 showed that the combination QIAamp® 293 extraction/RA1 performed much better than the combination EXTRAblood®/RA1 ( Figure 2B) , 294 stressing the need to evaluate the extraction and PCR methods together, as emphasized 295 earlier (19). Moreover, the combination EXTRAblood®/Elite MGB (recommended by the 296 manufacturer) performed significantly worse than the combination QiaAmp®/Elite MGB to 297 amplify low parasite concentrations (Figure 1 ), thus should be avoided. The evaluation of the 298 combination extraction / amplification methods is of peculiar importance for off-label use of 299 commercial PCR assays, particularly with cell-rich samples types, as its efficiency is 300 determining to detect very low parasite amounts. Furthermore, the validation of the entire 301 process is necessary to meet the requirements of quality assurance system. 302 Regarding the handiness and good laboratory practices, the mix provided in the kit contains 303 uracil-N-glycosylase (UNG) to limit carryover contaminations from previously amplified PCR 304 products. The kit does not include a standard to perform a curve to quantify parasite loads. 305 The PCR assay, the internal control and the positive control are purchased in three separate 306 vials, thus the management of batch traceability is not easy. 307 Several qPCR commercial assays are available to date to detect Toxoplasma DNA, but very 308 few have been evaluated using clinical samples or in routine use. A previous multicenter In the present study, we enrolled a smaller 312 amount of amniotic fluid samples (56), but the Toxoplasma ELITe MGB® assay showed also a 313 good concordance using these samples. 314 Taken together, this study showed that the Toxoplasma ELITe MGB® assay appears suitable 315 for prenatal diagnosis. However, a note of caution is in order when using cell-rich or 
